Agenus to present new clinical data on agen1181 at aacr 2021

Lexington, mass., march 10, 2021 (globe newswire) -- agenus inc. (nasdaq: agen), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that two abstracts on agen1181, agenus' fc-enhanced next-generation anti-ctla-4 antibody, were accepted for presentation at the american association for cancer research (aacr) annual meeting from april 10 - 15, 2021.
AGEN Ratings Summary
AGEN Quant Ranking